韩国青年成人缺血性卒中治疗的改善与临床结局的停滞
该研究基于韩国前瞻性多中心卒中登记,纳入2008-2019年18-50岁急性缺血性卒中患者7050例,分析治疗与结局的十年趋势。结果显示静脉溶栓和机械取栓率上升、二级预防改善,但1年死亡率和3个月改良Rankin量表评分无变化,1年复发率上升但校正后无显著差异。
要点
- 静脉溶栓率从9.5%升至13.8%,机械取栓率从3.2%升至9.2%(P趋势<0.01)。
- 非心源性轻型卒中双联抗血小板治疗从26.7%升至47.0%,房颤直接口服抗凝药从0.0%升至56.2%。
- 1年死亡率2.5%至2.3%,3个月改良Rankin量表评分0-1分68.3%至69.1%,均无变化。
核心结论
- 过去十年急性卒中治疗的实施改善未必然导致青年急性缺血性卒中患者结局改善,提示需要进一步进展。
研究设计与样本
- 基于韩国前瞻性多中心卒中登记,纳入2008-2019年住院的18-50岁急性缺血性卒中患者,共7050例(平均年龄43.1岁,男性71.9%),观察期分为2008-2010、2011-2013、2014-2016和2017-2019四个阶段。
主要发现
- 平均年龄从43.6岁降至42.9岁(P趋势=0.01),当前吸烟减少而肥胖增加,其他危险因素不变。
- 静脉溶栓率从2008-2010年的9.5%升至2017-2019年的13.8%,机械取栓率从3.2%升至9.2%(P趋势<0.01)。
- 门-针时间改善(P趋势<0.001),但发病-到院时间和门-穿刺时间保持不变。
- 二级预防包括非心源性轻型卒中双联抗血小板(26.7%至47.0%)、房颤直接口服抗凝药(0.0%至56.2%)和大动脉粥样硬化他汀(76.1%至95.3%)均增加(P趋势<0.01)。
- 1年死亡率(2011-2013年2.5% vs 2017-2019年2.3%)和3个月改良Rankin量表评分0-1分(68.3%至69.1%)及0-2分(87.6%至86.2%)保持不变;1年卒中复发率增加(4.1%至5.5%;P趋势=0.04),但校正性别和年龄后差异不显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is limited information on the delivery of acute stroke therapies and secondary preventive measures and clinical outcomes over time in young adults with acute ischemic stroke. This study investigated whether advances in these treatments improved outcomes in this population. METHODS: Using a prospective multicenter stroke registry in Korea, young adults (aged 18-50 years) with acute ischemic stroke hospitalized between 2008 and 2019 were identified. The observation period was divided into 4 epochs: 2008 to 2010, 2011 to 2013, 2014 to 2016, and 2017 to 2019. Secular trends for patient characteristics, treatments, and outcomes were analyzed. RESULTS: A total of 7050 eligible patients (mean age, 43.1; men, 71.9%) were registered. The mean age decreased from 43.6 to 42.9 years (Ptrend=0.01). Current smoking decreased, whereas obesity increased. Other risk factors remained unchanged. Intravenous thrombolysis and mechanical thrombectomy rates increased over time from 2008 to 2010 to 2017 to 2019 (9.5%-13.8% and 3.2%-9.2%, respectively; Ptrend<0.01). Door-to-needle time improved (Ptrend <.001), but onset-to-door and door-to-puncture times remained constant. Secondary prevention, including dual antiplatelets for noncardioembolic minor stroke (26.7%-47.0%), direct oral anticoagulants for atrial fibrillation (0.0%-56.2%), and statins for large artery atherosclerosis (76.1%-95.3%) increased (Ptrend<0.01). Outcome data were available from 2011. One-year mortality (2.5% in 2011-2013 and 2.3% in 2017-2019) and 3-month modified Rankin Scale scores 0 to 1 (68.3%-69.1%) and 0 to 2 (87.6%-86.2%) remained unchanged. The 1-year stroke recurrence rate increased (4.1%-5.5%; Ptrend=0.04), although the difference was not significant after adjusting for sex and age. CONCLUSIONS: Improvements in the delivery of acute stroke treatments did not necessarily lead to better outcomes in young adults with acute ischemic stroke over the past decade, indicating a need for further progress.
引用
- Kim J, Kim JY, Kang J, et al. Improvement in Delivery of Ischemic Stroke Treatments but Stagnation of Clinical Outcomes in Young Adults in South Korea. Stroke. 2023. PMID: 37942640. doi:10.1161/STROKEAHA.123.044619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。